PMS Registry
Company Name
Bayer Taiwan Co., Ltd.
Protocol Number
Title of Study
REFINE: Regorafenib observational study in hepatocellular carcinoma
Primary Objective
To evaluate the safety of regorafenib in patients with uHCC, including incidences of all treatment-emergent adverse events (TEAEs) and dose modifications due to TEAEs under real-world practice conditions.
Number of Sites
Period of Study
From:Jun 2018 to:Jun 2022
Number of Patients
IRB Approval Date
臺北榮民總醫院: 30Dec2017
國立臺灣大學醫學院附設醫院: 05Feb2018
臺中榮民總醫院: 01Mar2018
高雄醫學大學附設中和紀念醫院: 12Mar2018
戴德森醫療財團法人嘉義基督教醫院: 21Mar2018
中國醫藥大學附設醫院: 12Apr2018
國立成功大學醫學院附設醫院: 04May2018
馬偕紀念醫院: 9May2018
Publication Plan / Date